Head-to-head · free
Alibaba Group Holding Limited vs Pacific Biosciences of California
BABA vs PACB — return on capital, cash generation, margins and balance sheet side by side.
BABA
4 / 6
measures where BABA leads
PACB
2 / 6
measures where PACB leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | BABA · FY2026 | PACB · FY2025 |
|---|---|---|
| Revenue | $1.02T | — |
| Net income | $103.6B | (546.4M) |
| Revenue growth (yearly, multi-year) | 4.7% | — |
| Free cash flow | (50.7B) | (113.9M) |
| Free cash flow margin | -5.0% | — |
| Net cash / (debt) | (86.1B) | — |
| ROIC | 2.8% | — |
| Return on equity | 10.0% | -213.5% |
| Gross margin | 39.8% | 28.6% |
| Operating margin | 5.8% | -348.5% |
| Net debt / EBITDA | 1.32x | -3.47x |
Figures are as reported by each company; latest fiscal year shown.
Where Alibaba Group Holding Limited's cash went (FY2026)
- Capital spending
- $126.9B
- Buybacks
- $7.6B
- Dividends
- $33.7B
- Acquisitions
- $12.1B
- Net debt issued / (repaid)
- $39.0B
Where Pacific Biosciences of California's cash went (FY2025)
- Capital spending
- $2.7M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free